GlassScriptPhysician profile
Justin D Gull
NPI 1962600338
$4,002.93
in general payments reported to CMS, 2019-2025
16 companies · $2,541 in 2025
The $2,541 reported for 2025 was more than what 92% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $66.36 · 2021: $227 · 2022: $290 · 2023: $142 · 2024: $443 · 2025: $2,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Consulting Fee: $1,200 · Travel and Lodging: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.77 |
| Consulting Fee | $1,200.00 |
| Travel and Lodging | $290.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,056.44 | 2022-2025 | |
| Genzyme Corporation | $366.96 | 2022-2025 | |
| Glaxosmithkline, LLC. | $352.44 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $333.28 | 2019-2025 | Dupixent |
| Optinose US, INC. | $280.35 | 2019-2025 | |
| Stryker Corporation | $154.55 | 2020-2025 | Scopis Ent |
| Astrazeneca Pharmaceuticals LP | $122.97 | 2019-2022 | |
| Kaleo, INC. | $99.76 | 2021-2023 | Auvi-Q |
| Revance Therapeutics, INC. | $60.43 | 2025 | Daxxify |
| Intersect Ent, INC. | $44.60 | 2021 | |
| Inspire Medical Systems, INC. | $43.91 | 2025 | Inspire |
| Medtronic, INC. | $42.74 | 2025 | Propel, Stealthstation S8 Platform |
| Cochlear Americas | $17.22 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Circassia INC. | $14.64 | 2019 | |
| Welch Allyn | $12.64 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Gull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.